https://openbell.ai/ 2026-11-08T23:10:03.837Z hourly 1.0 https://openbell.ai/support 2026-11-08T23:10:03.837Z monthly 0.7 https://openbell.ai/privacy 2026-11-08T23:10:03.837Z monthly 0.5 https://openbell.ai/terms 2026-11-08T23:10:03.837Z monthly 0.5 https://openbell.ai/feed.json 2026-11-08T23:10:03.837Z hourly 0.8 https://openbell.ai/news/MTD:1794168112000 2026-11-08T20:01:52.000Z daily 0.9 https://cdn.brandfetch.io/MTD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mettler-Toledo Raises Full-Year 2026 Sales Outlook and Provides 2027 Guidance Mettler-Toledo raised its 2026 local-currency sales growth outlook to approximately 5%, from a prior range of 4% to 5%, citing strength in China and emerging markets. Third-quarter sales rose 6% to $1.1 billion, while adjusted EPS was $12.57; full-year 2026 adjusted EPS is forecast at $47.70 to $47.90. For 2027, the company expects approximately 5% local-currency sales growth and adjusted EPS of $52.50 to $53.50. Management also projects about $950 million in free cash flow and plans an equivalent amount of share repurchases in 2027. https://openbell.ai/news/TOKMAN:1794164516000 2026-11-08T19:01:56.000Z daily 0.9 https://cdn.brandfetch.io/TOKMAN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tokmanni Issues Profit Warning and Preliminary Q3 Results Tokmanni Group issued a profit warning and released preliminary third-quarter financial data ahead of its earnings report, citing a deviation from its previous expectations. The company announced the update in a press release on November 7, 2026; the article provides no specific financial figures or stock-market impact. https://openbell.ai/news/APLM:1794146586000 2026-11-08T14:03:06.000Z daily 0.9 https://cdn.brandfetch.io/APLM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Apollomics Announces Layoffs and Termination of Lung Cancer Trial Due to Cash Constraints Apollomics said in an SEC filing that severe cash constraints are prompting it to lay off all U.S. employees, including its CEO and CFO, and end operations related to its lung cancer clinical trial. The moves follow a failed late-stage blood cancer trial that did not show a survival benefit over chemotherapy alone. The company has scheduled an extraordinary shareholder meeting to vote on liquidation. https://openbell.ai/news/JELD:1794146574000 2026-11-08T14:02:54.000Z daily 0.9 https://cdn.brandfetch.io/JELD/w/400/h/400?c=1idopYfmtR7ZKg8QMud JELD-WEN Reports Q3 2026 Results, Strategic Review Outcome, and CFO Departure JELD-WEN reported higher adjusted earnings in Q3 2026, aided by tariff refunds and cost savings, despite weaker-than-expected demand for windows and doors. After a strategic review, it will retain its European business and pursue operational improvements under Christian Michel; CFO Stoddard is stepping down. The company maintained its full-year revenue and adjusted EBITDA guidance but now expects market volumes to decline in North America and Europe. It expects to complete debt refinancing by the end of November, extending maturities to 2031 while adding about $50 million in annual interest expense. https://openbell.ai/news/FC:1794146561000 2026-11-08T14:02:41.000Z daily 0.9 https://cdn.brandfetch.io/FC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Franklin Covey Reports Fiscal 2026 Financial Results and Fiscal 2027 Outlook Franklin Covey reported fiscal 2026 revenue of $261.5 million, down 2% year over year, while adjusted EBITDA edged up to $28.9 million. Fourth-quarter revenue was $70 million, and adjusted EBITDA increased 9% to $12.8 million. For fiscal 2027, the company forecasts revenue of $263 million to $273 million and adjusted EBITDA of $29 million to $34 million, plans to expand its sales hunting team by more than 20%, and expects to complete the transition of its China operations to a locally owned licensee by the end of the second quarter. Franklin Covey also repurchased about 1.6 million shares for $28.1 million during fiscal 2026. https://openbell.ai/news/FROG:1794146531000 2026-11-08T14:02:11.000Z daily 0.9 https://cdn.brandfetch.io/FROG/w/400/h/400?c=1idopYfmtR7ZKg8QMud JFrog Reports Earnings Beat and $76M SaaS Contract JFrog reported earnings above expectations, supported by growth in its cloud business. The company also announced a new multiyear SaaS contract valued at $76 million. https://openbell.ai/news/HLT:1794146514000 2026-11-08T14:01:54.000Z daily 0.9 https://cdn.brandfetch.io/HLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hilton Raises Full-Year Revenue Per Available Room (RevPAR) Forecast Hilton raised its full-year RevPAR growth forecast to 4%–4.5%, up from its prior guidance of 3%–3.5%. Leadership attributed the improved outlook to resilient global travel demand, while CEO Christopher Nassetta said business activity in the Middle East has been slightly softer than expected. https://openbell.ai/news/MLM:1794146511000 2026-11-08T14:01:51.000Z daily 0.9 https://cdn.brandfetch.io/MLM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Martin Marietta Announces 2027 Margin Growth Outlook and $500 Million Debt Repayment Plan Martin Marietta Materials projected aggregate pricing growth and margin expansion in 2027, supported by cost management, network optimization, and a full year of earnings from Lhoist, which it expects to help offset inflation. The company plans to repay approximately $500 million in debt over the coming weeks. It reaffirmed its commitment to an investment-grade credit rating and a target net debt-to-adjusted EBITDA ratio of 2.0 to 2.5. https://openbell.ai/news/MNTN:1794103412000 2026-11-08T02:03:32.000Z daily 0.9 https://cdn.brandfetch.io/MNTN/w/400/h/400?c=1idopYfmtR7ZKg8QMud MNTN, Inc. Faces Securities Investigation Following Q3 Earnings Miss and Sales Force Attrition MNTN reported third-quarter 2026 revenue of $80.3 million, below its $86 million–$89 million guidance, and adjusted EBITDA of $19.9 million, below its $22 million–$25 million outlook. Management attributed the shortfall to a failed sales-compensation restructuring that led about 40% of experienced quota-carrying sales staff to leave, and cut full-year revenue guidance to $311 million–$314 million. The company also replaced CEO Mark Douglas with Tony Weisman. Multiple law firms have opened investigations into whether MNTN or senior management made misleading statements about its sales organization and growth prospects. https://openbell.ai/news/TTAM:1794103380000 2026-11-08T02:03:00.000Z daily 0.9 https://cdn.brandfetch.io/TTAM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Titan America Announces Third Quarter 2026 Financial Results Titan America reported that third-quarter 2026 margins were pressured by market headwinds and higher energy costs. Unfavorable weather and an unplanned maintenance outage at its Roanoke Cement plant also negatively affected performance. The article did not provide revenue, profit, growth figures, or stock-price movements. https://openbell.ai/news/EWTX:1794103370000 2026-11-08T02:02:50.000Z daily 0.9 https://cdn.brandfetch.io/EWTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Edgewise Therapeutics Reportedly Explores Potential Sale Edgewise Therapeutics has reportedly attracted takeover interest and may have engaged advisers to explore a potential sale, according to a market alert circulated November 7, 2026. The company has not confirmed a definitive agreement or a formal strategic review process. https://openbell.ai/news/IONS:1794103359000 2026-11-08T02:02:39.000Z daily 0.9 https://cdn.brandfetch.io/IONS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Novartis Discontinues Development of Pelacarsen for Atherosclerotic Cardiovascular Disease Novartis will discontinue developing Ionis Pharmaceuticals’ RNA-targeting therapy pelacarsen for atherosclerotic cardiovascular disease after it failed to meet the primary endpoint in the Phase 3 Lp(a)HORIZON trial, reported in September 2026. Pelacarsen was designed as a monthly injection to lower lipoprotein(a), a cardiovascular risk factor. Novartis said a separate study of the drug in patients with calcific aortic valve stenosis will continue; the article provides no financial figures or stock-price impact. https://openbell.ai/news/USFD:1794103340000 2026-11-08T02:02:20.000Z daily 0.9 https://cdn.brandfetch.io/USFD/w/400/h/400?c=1idopYfmtR7ZKg8QMud US Foods and Performance Food Group Explore Potential Merger Performance Food Group and US Foods Holding Corp. agreed to share confidential information as they explore a potential merger, though PFG said the agreement does not guarantee a deal or set a timeline. US Foods confirmed discussions with its competitor. The talks follow reports that activist investor Sachem Head has urged PFG to consider a merger to improve profitability. https://openbell.ai/news/JNJ:1794103308000 2026-11-08T02:01:48.000Z daily 0.9 https://cdn.brandfetch.io/JNJ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Johnson & Johnson Reports Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis Johnson & Johnson reported that its Phase 3 trial of oral peptide ICOTYDE (icotrokinra) met its primary endpoint in biologic-naïve adults with active psoriatic arthritis. At Week 16, 58% of treated patients achieved an ACR20 response, compared with 41% on placebo. Safety findings were consistent with the drug’s established profile, with no new safety signals reported.